Not only does Roger Perlmutter, M.D., PhD., have the pull to lock down a fundraising round worth a half a billion dollars, he's now poached a former Merck & Co. colleague over to his new biotech Eikon ...
Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...
The Nasdaq logo is seen at the Nasdaq Market in New York City, U.S., September 16, 2025. REUTERS/Brendan McDermid Feb 4 (Reuters) - Drug developer Eikon Therapeutics said on Wednesday it had raised ...
Eikon Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO seeking a valuation of up to $908M with roughly 17.6M shares on offer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results